Immunomodulation and vaccination for atherosclerosis

Bibliography

• HANSSON GK, LIBBY P, SCHONBECK U, YAN ZQ: Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. (2002) 91(4):281–291.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review on the role ofinnate and acquired immunity in the development of atherosclerosis.
   Google Scholar
• BINDER CJ, CHANG MK, SHAW PX et al.: Innate and acquired immunity in atherogenesis. Nat. Med. (2002) 8(11):1218–1226.
   PubMed Web of Science ®Google Scholar
• ••An excellent review on currentunderstanding of pathogenesis of atherosclerosis.
   Google Scholar
• PEARSON AM: Scavenger receptors in innate immunity. Can: Opin. Immunol (1996) 8(1):20–28.
   PubMed Web of Science ®Google Scholar
• KRIEGER M: The other side of scavenger receptors: pattern recognition for host defense. Carr: Opin. Lipidol (1997) 8(5):275–280.
   PubMed Web of Science ®Google Scholar
• MUZIO M, NATOLI G, SAC CANI S, LEVRERO M, MANTOVANI A: The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J. Exp. Med. (1998) 187(12):2097–2101.
   PubMed Web of Science ®Google Scholar
• ALIPRANTIS AO, YANG RB, MARK MR et al.: Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science (1999) 285(5428):736–739.
   PubMed Web of Science ®Google Scholar
• FAURE E, EQUILS O, SIELING PA et aL: Bacterial lipopolysaccharide activates NF-kappaB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells. Differential expression of TLR-4 and TLR-2 in endothelial cells. Biol. Chem. (2000) 275(15):11058–11063.
   Google Scholar
• UNANUE ER, CEROTTINI JC: Antigen presentation. FASEB J. (1989) 3(13):2496–2502.
   PubMed Web of Science ®Google Scholar
• YEWDELL JVV, BENNINK JR: The binary logic of antigen processing and presentation to T cells. Cell (1990) 62(2):203–206.
   PubMed Web of Science ®Google Scholar
• BROWN MS, GOLDSTEIN JL: A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232(4746):34–47.
   PubMed Web of Science ®Google Scholar
• HEINECKE JW, BAKER L, ROSEN H, CHAIT A: Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J. Clin. Invest. (1986) 77(3):757–761.
   PubMed Web of Science ®Google Scholar
• PARTHASARATHY S, WIELAND E, STEINBERG D: A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA (1989) 86(3):1046–1050.
   PubMed Web of Science ®Google Scholar
• WITZTUM JL, STEINBERG D: Role of oxidized low density lipoprotein in atherogenesis. Clin. Invest. (1991) 88(6):1785–1792.
   Google Scholar
• EHRENWALD E, CHISOLM GM, FOX PL: Intact human ceruloplasmin wddatively modifies low density lipoprotein. Clin. Invest. (1994) 93(4):1493–1501.
   Google Scholar
• PIEDRAHITA JA, ZHANG SH, HAGAMAN JR, OLIVER PM, MAEDA N: Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. USA (1992) 89(10):4471–4475.
   PubMed Web of Science ®Google Scholar
• PLUMP AS, SMITH JD, HAYEK T et al.: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E- deficient mice created by homologous recombination in ES cells. Cell (1992) 71(2):343–353.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI S, BROWN MS, GOLDSTEIN JL, GERARD RD, HAMMER RE, HERZ J: Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery [see comments]. Clin. Invest. (1993) 92(2):883–893.
   Google Scholar
• ROSENFELD ME, YLA-HERTTUALA S, LIPTON BA, ORD VA, WITZTUM JL, STEINBERG D: Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am. J. Pathol. (1992) 140(2):291–300.
   PubMed Web of Science ®Google Scholar
• CLINTON SK, UNDERWOOD R, HAYES L, SHERMAN ML, KUFE DW, LIBBY P: Macrophage colony-stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am. J. Pathol (1992) 140(2):301–316.
   PubMed Web of Science ®Google Scholar
• SMITH JD, TROGAN E, GINSBERG M, GRIGAUX C, TIAN J, MIYATA M: Decreased atherosclerosis in mice deficient in both macrophage colony- stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. USA (1995) 92(18):8264–8268.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN JL, HO YK, BASU SK, BROWN MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Nati Acad. Sci. USA (1979) 76(1):333–337.
   PubMed Web of Science ®Google Scholar
• GRIFFITH RL, VIRELLA GT, STEVENSON HC, LOPES-VIRELLA MF: Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes. A possible mechanism of foam cell formation. J. Exp. Med. (1988) 168(3):1041–1059.
   Google Scholar
• ITABE H, TAKESHIMA E, IWASAKI H et al.: A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J. Biol. Chem. (1994) 269(21):15274–15279.
   Google Scholar
• SUZUKI H, KURIHARA Y, TAKEYA M et al.: A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature (1997) 386(6622):292–296.
   PubMed Web of Science ®Google Scholar
• FEBBRAIO M, PODREZ EA, SMITH JD et al.: Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. Clin. Invest. (2000) 105(8):1049–1056.
   Google Scholar
• KUME N, MORIWAKI H, KATAOKA H et al.: Inducible expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth muscle cells. Ann. NY Acad. Sci. (2000) 902:323–327.
   PubMed Web of Science ®Google Scholar
• XU XH, SHAH PK, FAURE E et al.: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation (2001) 104(25):3103–3108.
   PubMed Web of Science ®Google Scholar
• •See [29].
   Google Scholar
• VINK A, SCHONEVELD AH, VAN DER MEER JJ et al.: In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation (2002) 106(15):1985–1990.
   Google Scholar
• •See [29].
   Google Scholar
• EDFELDT K, SWEDENBORG J, HANSSON GK, YAN ZQ: Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation (2002) 105(10):1158–1161.
   PubMed Web of Science ®Google Scholar
• •These three studies provide evidence for a link between innate immunity and atherogenesis.
   Google Scholar
• WRIGHT SD, BURTON C, HERNANDEZ M et al.: Infectious agents are not necessary for murine atherogenesis [In Process Citation]. Exp. Med. (2000) 191(8):1437–1442.
   PubMed Web of Science ®Google Scholar
• NATHAN CE MURRAY HW, COHN ZA: The macrophage as an effector cell. N Engl. J. Med. (1980) 303(11):622–626.
   PubMed Web of Science ®Google Scholar
• VAN FURTH R: Current view on the mononuclear phagocyte system. Immunobiology (1982) 161(3-4):178–185.
   PubMed Web of Science ®Google Scholar
• ELHAGE R, MARET A, PIERAGGI MT, THIERS JC, ARNAL JF, BAYARD F: Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation (1998) 97(3):242–244.
   PubMed Web of Science ®Google Scholar
• JONASSON L, HOLM J, SKALLI O, GABBIANI G, HANSSON GK: Expression of class II transplantation antigen on vascular smooth muscle cells in human atherosclerosis. J. Clin. Invest. (1985) 76(1):125–131.
   PubMed Web of Science ®Google Scholar
• JONASSON L, HOLM J, SKALLI O, BONDJERS G, HANSSON GK: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis (1986) 6(2):131–138.
   PubMedGoogle Scholar
• ZHOU X: CD4+ T cells in atherosclerosis.Biomed. Pharmacother. (2003) 57(7):287–291.
   Google Scholar
• •A concise review specifically on the roles of CD4+ T cell subpopulations in atherosclerosis.
   Google Scholar
• HANSSON GK, HOLM J, JONASSON L: Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol (1989) 135(1):169–175.
   PubMed Web of Science ®Google Scholar
• STEMME S, FABER B, HOLM J, WIKLUND O, WITZTUM JL, HANSSON GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Nati Acad. Sci. USA (1995) 92(9):3893–3897.
   PubMed Web of Science ®Google Scholar
• ABRAHAM R, CHOUDHURY A, BASU SK, BAL V, RATH S: Disruption of T cell tolerance by directing a self antigen to macrophage-specific scavenger receptors. Immunol (1997) 158(9):4029–4035.
   Web of Science ®Google Scholar
• NICOLETTI A, CALIGIURI G, TORNBERG I, KODAMA T, STEMME S, HANSSON GK: The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur: j Immunol (1999) 29(2):512–521.
   PubMed Web of Science ®Google Scholar
• FROSTEGARD J, ULFGREN AK, NYBERG P et al.: Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Thl) and macrophage-stimulating cytokines. Atherosclerosis (1999) 145(1):33–43.
   PubMed Web of Science ®Google Scholar
• HANSSON GK, SEIFERT PS, OLSSON G, BONDJERS G: Immunohistochemical detection of macrophages and T lymphocytes in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler. Thromb. (1991) 11(3):745–750.
   PubMedGoogle Scholar
• ROSS R: Arteriosclerosis, an overview. In: Molecular Cardiovascular Medicine Haber E (Ed.), Scientific American, Inc. (1995):11–30.
   Google Scholar
• ZHOU X, STEMME S, HANSSON GK: Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice [see comments]. Am. J. Pathol (1996) 149(2):359–366.
   Google Scholar
• MOSMANN TR, SAD S: The expanding universe of T-cell subsets: Thl, Th2 and more [see comments]. Immunol Today (1996) 17(3):138–146.
   PubMedGoogle Scholar
• UYEMURA K, DEMER LL, CASTLE SC et al.: Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis.' Clin. Invest. (1996) 97(9):2130–2138.
   Google Scholar
• ZHOU X, PAULSSON G, STEMME S, HANSSON GK: Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. Clin. Invest. (1998) 101(8):1717–1725.
   Google Scholar
• POBER JS, GIMBRONE MA JR: Expression of Ia-like antigens by human vascular endothelial cells is inducible M vitro: demonstration by monoclonal antibody binding and immunoprecipitation. Proc. Nati Acad. Sci. USA (1982) 79(21):6641–6645.
   PubMed Web of Science ®Google Scholar
• HANSSON GK, JONASSON L, HOLM J, CLOWES MM, CLOWES AW: Gamma-interferon regulates vascular smooth muscle proliferation and Ia antigen expression in vivo and M vitro. Circ. Res. (1988) 63(4):712–719.
   PubMed Web of Science ®Google Scholar
• HANSSON GK, HELLSTRAND M, RYMO L, RUBBIA L, GABBIANI G: Interferon gamma inhibits both proliferation and expression of differentiation-specific alpha-smooth muscle actin in arterial smooth muscle cells. J. Exp. Med. (1989) 170(5):1595–1608.
   PubMed Web of Science ®Google Scholar
• AMENTO EP, EHSANI N, PALMER H, LIBBY P: Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscier. Thromb. (1991) 11(5):1223–1230.
   PubMed Web of Science ®Google Scholar
• ARNMAN V, STEMME S, RYMO L, RISBERG B: Interferon-gamma modulates the fibrinolytic response in cultured human endothelial cells. Thromb. Res. (1995) 77(5):431–440.
   PubMed Web of Science ®Google Scholar
• SCHEIBENBOGEN C, MOSER H, KRAUSE S, ANDREESEN R: Interferon-gamma-induced expression of tissue factor activity during human monocyte to macrophage maturation. Haemostasis (1992) 22(4):173–178.
   PubMedGoogle Scholar
• DANSKY HM, CHARLTON SA, HARPER MM, SMITH JD: T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. USA (1997) 94(9):4642–4646.
   PubMed Web of Science ®Google Scholar
• DAUGHERTY A, PURE E, DELFEL-BUTTEIGER D et al: The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice." Clin. Invest. (1997) 100(6):1575–1580.
   Google Scholar
• GUPTA S, PABLO AM, JIANG XC, WANG N, TALL AR, SCHINDLER C: IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. I. Clin. Invest. (1997) 99(11):2752–2761.
   PubMed Web of Science ®Google Scholar
• ZHOU X, NICOLETTI A, ELHAGE R, HANSSON GK: Transfer of CD4H T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation (2000) 102(24):2919–2922.
   PubMed Web of Science ®Google Scholar
• •Direct evidence of proatherogenic role of CD4+ T cells in murine atherosclerotic model.
   Google Scholar
• WHITMAN SC, RAVISANKAR P, ELAM H, DAUGHERTY A: Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice. Am. J. Pathol (2000) 157(6):1819–1824.
   PubMed Web of Science ®Google Scholar
• BUONO C, COME CE, STAVRAKIS G, MAGUIRE GE CONNELLY PW, LICHTMAN AH: Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler. Thromb. Vasc. Biol. (2003) 23(3):454–460.
   PubMed Web of Science ®Google Scholar
• LAURAT E, POIRIER B, TUPIN E et al: In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation (2001) 104(2):197–202.
   PubMed Web of Science ®Google Scholar
• LEE TS, YEN HC, PAN CC, CHAU LY: The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. (1999) 19(3):734–742.
   PubMed Web of Science ®Google Scholar
• DAVENPORT P, TIPPING PG: The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am. J. Pathol. (2003) 163(3):1117–1125.
   PubMed Web of Science ®Google Scholar
• LIBLAU RS, SINGER SM, MCDEVITT HO: Thl and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases [see comments]. Immunol Today(1995) 16(1):34–38.
   PubMedGoogle Scholar
• SAOUDI A, SIMMONDS S, HUITINGA I, MASON D: Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells [see comments]. J. Exp. Med. (1995) 182(2):335–344.
   PubMed Web of Science ®Google Scholar
• FALCONE M, BLOOM BR: AT helper cell 2 (Th2) immune response against non-self antigens modifies the cytokine profile of autoimmune T cells and protects against experimental allergic encephalomyelitis. J. Exp. Med. (1997) 185(5):901–907.
   PubMed Web of Science ®Google Scholar
• DE WAAL MALEFYT R, HAANEN J, SPITS H et al.: Interleuldn 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. (1991) 174(4):915–924.
   Google Scholar
• CONSTANT SL, BOTTOMLY K: Induction of Thl and Th2 CD4+ T cell responses: the alternative approaches. Ann. Rev. Immunol (1997) 15:297–322.
   PubMed Web of Science ®Google Scholar
• MALLAT Z, BESNARD S, DURIEZ M et al.: Protective role of interleukin-10 in atherosclerosis. Circ. Res. (1999) 85(8):e17–e24.
   PubMed Web of Science ®Google Scholar
• •See [71].
   Google Scholar
• VON DER THUSEN JH, KUIPERJ, FEKKES ML, DE VOS P, VAN BERKEL TJ, BIESSEN EA: Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J. (2001) 15(14):2730–2732.
   PubMedGoogle Scholar
• •See [71].
   Google Scholar
• PINDERSKI LJ, FISCHBEIN MP, SUBBANAGOUNDER G et al.: Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ. Res. (2002) 90(10):1064–1071.
   PubMed Web of Science ®Google Scholar
• •See [71].
   Google Scholar
• CALIGIURI G, RUDLING M, OLLIVIER V et al.: Interleuldn-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. MM. Med. (2003) 9(1-2):10–17.
   Google Scholar
• •Four studies show anti-inflammatory and atheroprotective effects of IL-10 in mtuine atherosclerotic models.
   Google Scholar
• ROOK AH, KEHRL JH, WAKEFIELD LM et al.: Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J. Immunol (1986) 136(10):3916–3920.
   PubMed Web of Science ®Google Scholar
• RANGES GE, FIGARI IS, ESPEVIK T, PALLADINO MJ: Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.' Exp. Med. (1987) 166(4):991–998.
   Google Scholar
• SASAKI H, POLLARD RB, SCHMITT D, SUZUKI F: Transforming growth factor-beta in the regulation of the immune response. Clin. Immunol Immunopathol (1992) 65(1):1–9.
   PubMedGoogle Scholar
• MAJESKY MW, LINDNER V, TWARDZIK DR, SCHWARTZ SM, REIDY MA: Production of transforming growth factor beta 1 during repair of arterial injury.' Clin. Invest. (1991) 88(3):904–910.
   Google Scholar
• NIKOL S, ISNER JM, PICKERING JG, KEARNEY M, LECLERC G, WEIR L: Expression of transforming growth factor-beta 1 is increased in human vascular restenosis lesions. .1 Clin. Invest. (1992) 90(4):1582–1592.
   Google Scholar
• GRAINGER DJ, KEMP PR, METCALFE JC et al.: The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis [see comments]. Nat. Med. (1995) 1(1):74–79.
   PubMed Web of Science ®Google Scholar
• ROBERTSON AK, RUDLING M, ZHOU X, GORELIK L, FLAVELL RA, HANSSON GK: Disruption of TGF-{beta} signaling in T cells accelerates atherosclerosis.' Clin. Invest. (2003) 112(9):1342–1350.
   Google Scholar
• ••See [80].
   Google Scholar
• GOJOVA A, BRUN V, ESPOSITO B et al: Specific abrogation of transforming growth factor-{heta} signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood (2003) 14:14.
   Google Scholar
• ••See [80].
   Google Scholar
• MALLAT Z, GOJOVA A, BRUN Vet al.: Induction of a regulatory T cell type 1 response reduces the development of atherosclerosis in apolipoprotein E-knockout mice. Circulation (2003) 108(10):1232–1237.
   Google Scholar
• ••These three important works provideevidence for the role of Treg in the early stages of atherosclerosis.
   Google Scholar
• SOHMA Y, SASANO H, SHIGA R et at.: Accumulation of plasma cells in atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Proc. Natl. Acad. Sci. USA (1995) 92(11):4937–4941.
   Google Scholar
• ZHOU X, HANSSON GK: Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scandj Immunol (1999) 50(1):25–30.
   PubMed Web of Science ®Google Scholar
• PARUMS D, MITCHINSON MJ: Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Atherosclerosis (1981) 38(1-2):211–216.
   PubMed Web of Science ®Google Scholar
• PARUMS DV, DUNN DC, DIXON AK, MITCHINSON MJ: Characterization of inflammatory cells in a patient with chronic periaortitis. Am. Cardiovasc. Pathol (1990) 3(2):121–129.
   PubMedGoogle Scholar
• NORDIN-FREDRIKSON G, HEDBLAD B, BERGLUND G, NILSSON J: Plasma oxidized LDL: a predictor for acute myocardial infarction? Intern. Med. (2003) 253(4):425–429.
   Web of Science ®Google Scholar
• HOLVOET P, HARRIS TB, TRACY RP et al.: Association of high coronary heart disease risk status with circulating oxidized LDL in the well-functioning elderly: findings from the Health, Aging, and Body Composition study. Arteriosc/er. Thromb. Vasc. Biol. (2003) 23(8):1444–1448.
   PubMed Web of Science ®Google Scholar
• SALONEN JT, YLA-HERTTUALA S, YAMAMOTO R et al.: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (1992) 339(8798):883–887.
   PubMed Web of Science ®Google Scholar
• YLA-HERTTUALA S, PALINSKI W, BUTLER SW, PICARD S, STEINBERG D, WITZTUM JL: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler. Thromb. (1994) 14(1):32–40.
   PubMed Web of Science ®Google Scholar
• PALINSKI W, HORKKO S, MILLER E et al.: Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. .1. Clin. Invest. (1996) 98(3):800–814.
   Google Scholar
• SEIFERT PS, HANSSON GK: Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis (1989) 9(6):802–811.
   PubMedGoogle Scholar
• SEIFERT PS, HUGO F, HANSSON GK, BHAKDI S: Prelesional complement activation in experimental atherosclerosis. Terminal C5b-9 complement deposition coincides with cholesterol accumulation in the aortic intima of hypercholesterolemic rabbits. Lab. Invest. (1989) 60(6):747–754.
   Google Scholar
• BUONO C, COME CE, WITZTUM JL et al.: Influence of C3 deficiency on atherosclerosis. Circulation (2002) 105(25):3025–3031.
   PubMed Web of Science ®Google Scholar
• GEERTINGER P, SORENSEN H: Complement and arteriosclerosis. Atherosclerosis (1973) 18(1):65–71.
   PubMed Web of Science ®Google Scholar
• VOLANAKIS JE: Human C-reactive protein: expression, structure, and function. MM. Immunol (2001) 38(2-3):189–197.
   PubMed Web of Science ®Google Scholar
• PEPYS MB, HIRSCHFIELD GM: C-reactive protein: a critical update. Clin. Invest. (2003) 111(12):1805–1812.
   Google Scholar
• BHAKDI S, TORZEWSKI M, KLOUCHE M, HEMMES M: Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arteciosder. Thromb. Vasc. Biol. (1999) 19(10):2348–2354.
   PubMed Web of Science ®Google Scholar
• PASCERI V, WILLERSON JT, YEH ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation (2000) 102(18):2165–2168.
   PubMed Web of Science ®Google Scholar
• ZWAKA TP, HOMBACH V, TORZEWSKI J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation (2001) 103(9):1194–1197.
   PubMed Web of Science ®Google Scholar
• NICOLETTI A, KAVERI S, CALIGIURI G, BARIETY J, HANSSON GK: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. Clin. Invest. (1998) 102(5):910–918.
   Google Scholar
• CALIGIURI G, NICOLETTI A, POIRIER B, HANSSON GK: Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. Clin. Invest. (2002) 109(6):745–753.
   Google Scholar
• •This study demonstrates that B cell-associated protective immunity develops during atherosclerosis and reduces disease progression.
   Google Scholar
• PICKER LJ, KISHIMOTO TK, SMITH CW, WARNOCK RA, BUTCHER EC: ELAM-1 is an adhesion molecule for skin-homing T cells [see comments]. Nature (1991) 349(6312):796–799.
   PubMed Web of Science ®Google Scholar
• CYBULSKY MI, GIMBRONE MA JR: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science (1991) 251(4995):788–791.
   PubMed Web of Science ®Google Scholar
• VAN DER WAL AC, DAS PK, TIGGES AJ, BECKER AE: Adhesion molecules on the endothelium and mononuclear cells in human atherosclerotic lesions. Am. J. Pathol (1992) 141(6):1427–1433.
   PubMed Web of Science ®Google Scholar
• ELICES MJ, OSBORN L, TAKADA Y et al.: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/ fibronectin binding site. Cell (1990) 60(4):577–584.
   PubMed Web of Science ®Google Scholar
• DONG ZM, CHAPMAN SM, BROWN AA, FRENETTE PS, HYNES RO, WAGNER DD: The combined role of P- and E-selectins in atherosclerosis. J. Clin. Invest. (1998) 102(1):145–152.
   PubMed Web of Science ®Google Scholar
• DONG ZM, BROWN AA, WAGNER DD: Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation (2000) 101(19):2290–2295.
   PubMed Web of Science ®Google Scholar
• COLLINS RG, VELJI R, GUEVARA NV, HICKS MJ, CHAN L, BEAUDET AL: P-Selectin or intercellular adhesion molecule (ICAM)-1 deficiency substantially protects against atherosclerosis in apolipoprotein E-deficient mice. 1 Exp. Med. (2000) 191(1):189–194.
   Google Scholar
• MANKA D, COLLINS RG, LEY K, BEAUDET AL, SAREMBOCK IJ: Absence of p-selectin, but not intercellular adhesion molecule-1, attenuates neointimal growth after arterial injury in apolipoprotein e-deficient mice. Circulation (2001) 103(7):1000–1005.
   PubMed Web of Science ®Google Scholar
• PHILLIPS JVV, BARRINGHAUS KG, SANDERS JM et al.: Single injection of P-selectin or P-selectin glycoprotein ligand-1 monoclonal antibody blocks neointima formation after arterial injury in apolipoprotein E-deficient mice. Circulation (2003) 107(17):2244–2249.
   PubMed Web of Science ®Google Scholar
• SHIH PT, BRENNAN ML, VORA DK et al.: Blocking very late antigen-4 integrin decreases leukocyte entry and fatty streak formation in mice fed an atherogenic diet. Circ. Res. (1999) 84(3):345–351.
   PubMed Web of Science ®Google Scholar
• CYBULSKY MI, IIYAMA K, LI H et al.: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. (2001) 107(10):1255–1262.
   PubMed Web of Science ®Google Scholar
• MUKHERJEE TK, DINH H, CHAUDHURI G, NATHAN L: Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc. Nati Acad. Sci. USA (2002) 99(6):4055–4060.
   PubMed Web of Science ®Google Scholar
• COLLINS T, KORMAN AJ, WAKE CT et al.: Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc. Nati Acad. Sci. USA (1984) 81(15):4917–4921.
   PubMed Web of Science ®Google Scholar
• GIACHELLI CM, LOMBARDI D, JOHNSON RJ, MURRY CE, ALMEIDA M: Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am.j Pathol (1998) 152(2):353–358.
   PubMed Web of Science ®Google Scholar
• YLA-HERTTUALA S, LIPTON BA, ROSENFELD ME et al: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc. Natl. Acad. Sci. USA (1991) 88(12):5252–5256.
   PubMed Web of Science ®Google Scholar
• NELKEN NA, COUGHLIN SR, GORDON D, WILCOX JN: Monocyte chemoattractant protein-1 in human atheromatous plaques. Clin. Invest. (1991) 88(4):1121–1127.
   Google Scholar
• BORING L, GOSLING J, CHENSUE SW et al.: Impaired monocyte migration and reduced type 1 (Thl) cytokine responses in C-C chemokine receptor 2 knockout mice../. Clin. Invest. (1997) 100(10):2552–2561.
   Google Scholar
• GU L, OKADA Y, CLINTON SK et a/.: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Ma Cell (1998) 2(2):275–281.
   Google Scholar
• BORING L, GOSLING J, CLEARY M, CHARO IF: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 394(6696):894–897.
   PubMed Web of Science ®Google Scholar
• GOSLING J, SLAYMAKER S, GU L et al: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B.j Clin. Invest. (1999) 103(6):773–778.
   Google Scholar
• NI W, EGASHIRA K, KITAMOTO S et al.: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation (2001) 103(16):2096–2101.
   PubMed Web of Science ®Google Scholar
• AIELLO RJ, BOURASSA PA, LINDSEY S et al.: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arteriosclec Thromb. Vasc. Biol. (1999) 19(6):1518–1525.
   PubMed Web of Science ®Google Scholar
• ROQUE M, KIM WJ, GAZDOIN M et al.: CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arteriosclec Vasc. Biol. (2002) 22(4):554–559.
   PubMed Web of Science ®Google Scholar
• LUCAS AD, BURSILL C, GUZIK TJ, SADOWSKI J, CHANNON KM, GREAVES DR: Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation (2003) 108(20)2498–2504.
   Google Scholar
• CHANDRASEKAR B, MUMMIDI S, PERLA RP et al.: Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway. Biochern. 1 (2003) 373\(Pt 2):547–558.
   Google Scholar
• SCHONBECK U, LIBBY P: CD40 signaling and plaque instability. Circ. Res. (2001) 89(12):1092–1103.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review on the role of CD40/CD4OL in atherogenesis.
   Google Scholar
• MACH F, SCHONBECK U, SUKHOVA GK, ATKINSON E, LIBBY P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 394(6689):200–203.
   PubMed Web of Science ®Google Scholar
• LUTGENS E, GORELIK L, DAEMEN MJ et al.: Requirement for CD154 in the progression of atherosclerosis. Nat. Med. (1999) 5(11):1313–1316.
   PubMed Web of Science ®Google Scholar
• KIM KS, DENTON MD, CHANDRAKER A et al.: CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis. Am. Pathol (2001) 158(3):977–986.
   PubMed Web of Science ®Google Scholar
• DE BOER OJ, HIRSCH F, VAN DER WAL AC, VAN DER LOOS CM, DAS PK, BECKER AE: Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation. Atherosclerosis (1997) 133(2):227–234.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA T, GOEK O, ZHANG X et al.: Be novo expression of killer immunoglobulin-like receptors and signaling proteins regulates the cytotoxic function of CD4 T cells in acute coronary syndromes. Circ. Res. (2003) 93(2):106–113.
   PubMed Web of Science ®Google Scholar
• •New information on T cell regulation in the lesions.
   Google Scholar
• NO AUTHORS LISTED: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344(8934):1383–1389.
   PubMed Web of Science ®Google Scholar
• KWAK B, MULHAUPT F, MYIT S, MACH F: Statins as a newly recognized type of immunomodulator. Nat. Med. (2000) 6(12):1399–1402.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI R, ENGLEMAN EG: Interrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferation. Biol. Chen]. (1991) 266(19):12216–12222.
   PubMed Web of Science ®Google Scholar
• RUDICH SM, MONGINI PK, PEREZ RV, KATZNELSON S: HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation. Transplant. Proc. (1998) 30(4):992–995.
   PubMed Web of Science ®Google Scholar
• ROMANO M, DIOMEDE L, SIRONI M et al.: Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. (2000) 80(7):1095–1100.
   PubMed Web of Science ®Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7(6):687–692.
   PubMed Web of Science ®Google Scholar
• SCHONBECK U, GERDES N, VARO N et al.: Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD4OL expression in human vascular cells. Circulation (2002) 106(23):2888–2893.
   PubMed Web of Science ®Google Scholar
• BACKLUND J, TRESCHOW A, BOCKERMANN R et al: Glycosylation of Type II collagen is of major importance for T cell tolerance and pathology in collagen-induced arthritis. Ear: I Innnunol (2002) 32(12):3776–3784.
   PubMed Web of Science ®Google Scholar
• WEINER HL, SELKOE DJ: Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 420(6917):879–884.
   PubMed Web of Science ®Google Scholar
• YLA-HERTTUALA S, PALINSKI W, ROSENFELD ME et al: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. Clin. Invest. (1989) 84(4):1086–1095.
   Google Scholar
• HABERLAND ME, FONG D, CHENG L: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science (1988) 241(4862):215–218.
   PubMed Web of Science ®Google Scholar
• PALINSKI W, ROSENFELD ME, YLA-HERTTUALA S et al.: Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA (1989) 86(4):1372–1376.
   PubMed Web of Science ®Google Scholar
• PALINSKI W, ORD VA, PLUMP AS, BRESLOW JL, STEINBERG D, WITZTUM JL: ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler: Thromb. (1994) 14(4):605–616.
   Google Scholar
• SALONEN JT, KORPELA H, SALONEN R, NYYSSONEN K: Precision and reproducibility of ultrasonographic measurement of progression of common carotid artery atherosclerosis [letter; comment]. Lancet (1993) 341(8853):1158–1159.
   PubMed Web of Science ®Google Scholar
• TERKELTAUB R, BANKA CL, SOLAN J, SANTORO D, BRAND K, CURTISS LK: Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler. Tbromb. (1994) 14(1):47–53.
   PubMedGoogle Scholar
• JOVINGE S, ARES MP, KALLIN B, NILSSON J: Human monocytes/ macrophages release TNF-alpha in response to Ox-LDL. Arterioscler. TIMM& V3SC. (1996) 16(12):1573–1579.
   Google Scholar
• QUINN MT, PARTHASARATHY S, FONG LG, STEINBERG D: addatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA (1987) 84(9):2995–2998.
   PubMed Web of Science ®Google Scholar
• SEIFERT PS, KAZATCHKINE MD: Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position. Ma Irninunol. (1987) 24(12):1303–1308.
   PubMed Web of Science ®Google Scholar
• ARDLIE NG, SELLEY ML, SIMONS LA: Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis (1989) 76(2-3):117–124.
   PubMed Web of Science ®Google Scholar
• AUTIO I, JAAKKOLA O, SOLAKIVI T, NIKKARI T: Oxidized low-density lipoprotein is chemotactic for arterial smooth muscle cells in culture. FEBS Lett. (1990) 277(1-2):247–249.
   PubMed Web of Science ®Google Scholar
• FROSTEGARD J, NILSSON J, HAEGERSTRAND A, HAMSTEN A, WIGZELL H, GIDLUND M: Oxidized low density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc. Natl. Acad. Sci. USA (1990) 87(3):904–908.
   PubMed Web of Science ®Google Scholar
• KUGIYAMA K, KERNS SA, MORRISETT JD, ROBERTS R, HENRY PD: Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature (1990) 344(6262):160–162.
   PubMed Web of Science ®Google Scholar
• DRAKE TA, HANNANI K, FEI HH, LAVI S, BERLINER JA: Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. Ain. J. Pathol (1991) 138(3):601–607.
   PubMed Web of Science ®Google Scholar
• LATRON Y, CHAUTAN M, ANFOSSO F et al.: Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler. Tbromb. (1991) 11(6):1821–1829.
   PubMedGoogle Scholar
• KUME N, CYBULSKY MI, GIMBRONE MJ: Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. Clin. Invest. (1992) 90(3):1138–1144.
   Google Scholar
• STIKO-RAHM A, HULTGARDH-NILSSON A, REGNSTROM J, HAMSTEN A, NILSSON J: Native and oxidized LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arterioscler. Tbromb. (1992) 12(9):1099–1109.
   PubMedGoogle Scholar
• GERSZTEN RE, LUSCINSKAS FW, DING HT et al.: Adhesion of memory lymphocytes to vascular cell adhesion molecule-1- transduced human vascular endothelial cells under simulated physiological flow conditions in vitro [see comments]. Circ. Res. (1996) 79(6):1205–1215.
   PubMed Web of Science ®Google Scholar
• MUELLER R, KRAHL T, SARVETNICK N: Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. I Exp. Med. (1996) 184(3):1093–1099.
   PubMed Web of Science ®Google Scholar
• TORZEWSKI J, OLDROYD R, LACHMANN P, FITZSIMMONS C, PROUDFOOT D, BOWYER D: Complement-induced release of monocyte chemotactic protein-1 from human smooth muscle cells. A possible initiating event in atherosclerotic lesion formation. Arterioscler: Thromb. Vase. Biol. (1996) 16(5):673–677.
   PubMed Web of Science ®Google Scholar
• PALINSKIW, MILLER E, WITZTUM JL: Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc. Nail Acad. ScL USA (1995) 92(3):821–825.
   PubMed Web of Science ®Google Scholar
• AMELI S, HULTGARDH NA, REGNSTROM J et al: Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler. Thromb. Vase. Biol. (1996) 16(8):1074–1079.
   PubMed Web of Science ®Google Scholar
• ALVING CR, SWARTZ GM JR, WASSEF NM et al.: Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. I Lab. Clin. Med. (1996) 127(1):40–49.
   PubMed Web of Science ®Google Scholar
• GEORGE J, AFEK A, GILBURD B et al.: Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis (1998) 138(1):147–152.
   PubMed Web of Science ®Google Scholar
• FREIGANG S, HORKKO S, MILLER E, WITZTUM JL, PALINSKI W: Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler. Thromb. Vase. Biol. (1998) 18(12):1972–1982.
   PubMed Web of Science ®Google Scholar
• ZHOU X, CALIGIURI G, HAMSTEN A, LEFVERT AK, HANSSON GK: LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler: Thromb. Vase. Biol. (2001) 21(1):108–114.
   PubMed Web of Science ®Google Scholar
• NORDIN-FREDRIKSON G, SODERBERG I, LINDHOLM M et al.: Inhibition of atherosclerosis in ApoE-null mice by immunization with ApoB-100 peptide sequences. Arterioscler: Thromb. Vase. Biol. (2003) 23(5):879–884.
   PubMed Web of Science ®Google Scholar
• •This study identifies for the first time that certain peptide sequences in apoB-100 can inhibit atherosclerosis in murine model.
   Google Scholar
• BINDER CJ, HORKKO S, DEWAN A et al.: Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. (2003) 9(6):736–743.
   PubMed Web of Science ®Google Scholar
• •This interesting paper demonstrates a molecular mimicry between epitopes of oxLDL and S. pneumoniae and suggests that such an immune response can have beneficial effects in the prevention of atherosclerosis.
   Google Scholar
• FROSTEGARD J, KJELLMAN B, GIDLUND M, ANDERSSON B, JINDAL S, KIESSLING R: Induction of heat shock protein in monocytic cells by oxidized low density lipoprotein. Atherosclerosis (1996) 121(1):93–103.
   PubMed Web of Science ®Google Scholar
• KIESSLING R, GRONBERG A, IVANYI J et al.: Role of hsp60 during autoimmune and bacterial inflammation. Immunol Rev. (1991) 121:91–111.
   PubMed Web of Science ®Google Scholar
• WICK G: Atherosclerosis-an autoimmune disease due to an immune reaction against heat-shock protein 60. Herz (2000) 25(2):87–90.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review specifically focused on the relationship between HSP and atherosclerosis.
   Google Scholar
• BERBERIAN PA, MYERS W, TYTELL M, CHALLA V, BOND MG: Immunohistochemical localization of heat shock protein-70 in normal- appearing and atherosclerotic specimens of human arteries. Am. J. Pathol (1990) 136(1):71–80.
   PubMed Web of Science ®Google Scholar
• XU Q, KLEINDIENST R, WAITZ W, DIETRICH H, WICK G: Increased expression of heat shock protein 65 coincides with a population of infiltrating T lymphocytes in atherosclerotic lesions of rabbits specifically responding to heat shock protein 65. J. Clin. Invest. (1993) 91(02693–2702.
   PubMed Web of Science ®Google Scholar
• XU Q, SCHETT G, PERSCHINKA H et al.: Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation (2000) 102(1):14–20.
   PubMed Web of Science ®Google Scholar
• XU Q, WILLEIT J, MAROSI M et al.: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis [see comments]. Lancet (1993) 341(8840255–259.
   Google Scholar
• FROSTEGARD J, LEMNE C, ANDERSSON B, VAN DER ZEE R, KIESSLING R, DE FAIRE U: Association of serum antibodies to heat-shock protein 65 with borderline hypertension. Hypertension (1997) 29(1 Pt 1):40–44.
   Google Scholar
• XU Q, KIECHL S, MAYR M et al: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study [see comments]. Circulation (1999) 100(11):1169–1174.
   PubMed Web of Science ®Google Scholar
• MAYR M, METZLER B, KIECHL S et al: Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia cob and Cblamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation (1999) 99(12):1560–1566.
   PubMed Web of Science ®Google Scholar
• XU Q, DIETRICH H, STEINER HJ et al: Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscler. Thromb. (1992) 12(7):789–799.
   PubMedGoogle Scholar
• GEORGE J, SHOENFELD Y, AFEK A et al.: Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein-65. Arterioscler: Thromb. Vasc. Biol. (1999) 19(3):505–510.
   PubMed Web of Science ®Google Scholar
• AFEK A, GEORGE J, GILBURD B et al: Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. Autoimmun. (2000) 14(2):115–121.
   Web of Science ®Google Scholar
• MARON R, SUKHOVA G, FARIA AM et al.: Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation (2002) 106(13):1708–1715.
   PubMed Web of Science ®Google Scholar
• •A very interesting study demonstrates by mucosal administration of HSP that the nasal vaccination can reduce atherosclerosis formation in murine model.
   Google Scholar
• HARATS D, YACOV N, GILBURD B, SHOENFELD Y, GEORGE J: Oral tolerance with heat shock protein 65 attenuates Mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic lesions. Am. Coll Cardiol (2002) 40(7):1333–1338.
   PubMed Web of Science ®Google Scholar
• SUN JB, RASK C, OLSSON T, HOLMGREN J, CZERKINSKY C: Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Nati Acad. ScL USA (1996) 93(14):7196–7201.
   PubMed Web of Science ®Google Scholar
• FARIA AM, WEINER HL: Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. (1999) 73:153–264.
   PubMed Web of Science ®Google Scholar
• GEORGE J, HARATS D, GILBURD B et al.: Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation (1999) 99(17):2227–2230.
   PubMed Web of Science ®Google Scholar
• SHERER Y, TENENBAUM A, PRAPROTNIK S et al.: Coronary artery disease but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I, and oxidized LDL antibodies. Cardiology (2001) 95(1):20–24.
   PubMed Web of Science ®Google Scholar
• GEORGE J, AFEK A, GILBURD B et al.: Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation (1998) 98(11):1108–1115.
   PubMed Web of Science ®Google Scholar
• HASUNUMA Y, MATSUURA E, MAKITA Z, KATAHIRA T, NISHI S, KOIKE T: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in wddatively modified low-density lipoprotein uptake by macrophages. Clin. Exp. Immunol. (1997) 107(3):569–573.
   PubMed Web of Science ®Google Scholar
• SAIKKU P, LEINONEN M, MATTILA K et al.: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet (1988) 2(8618):983–986.
   PubMed Web of Science ®Google Scholar
• KUO CC, GOWN AM, BENDITT EP, GRAYSTON JT: Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arteriosclec Thromb. (1993) 13(10):1501–1504.
   PubMedGoogle Scholar
• LEINONEN M, SAIKKU P: Evidence for infectious agents in cardiovascular disease and atherosclerosis. Lancet Infect. Dis. (2002) 2(1):11–17.
   PubMed Web of Science ®Google Scholar
• MOAZED TC, CAMPBELL LA, ROSENFELD ME, GRAYSTON JT, KUO CC: Chlarnydia pneumoniaeinTection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.' Infect. Dis. (1999) 180(1):238–241.
   Google Scholar
• FONG IW, CHIU B, VIIRA E, JANG D, MAHONY JB: Be novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect. Immun. (1999) 67(11):6048–6055.
   PubMed Web of Science ®Google Scholar
• AALTO-SETALA K, LAITINEN K, ERKKILA L et al.: Chlarnydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscier. DIF017111. V3SC. Biol. (2001) 21(4):578–584.
   Google Scholar
• CALIGIURI G, ROTTENBERG M, NICOLETTI A, WIGZELL H, HANSSON GK: Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation (2001) 103(23):2834–2838.
   PubMed Web of Science ®Google Scholar
• O'CONNOR CM, DUNNE MW, PFEFFER MA et al.: Azithromycin for the second prevention of coronary heart disease events. The WIZARD study: a randomized controlled trial. JAMA (2003) 290(11):1459–1466.
   Google Scholar
• •This large trial reports that there is no beneficial effect of antibiotic on myocardial infarction and subsequent cardiovascular events, which argues against Cp as a cause of coronary heart disease.
   Google Scholar
• EPSTEIN SE, ZHOU YF, ZHU J: Infection and atherosclerosis: emerging mechanistic paradigms. Circulation (1999) 100(4):e20–e28.
   PubMed Web of Science ®Google Scholar
• SODERBERG-NAUCLER C, NELSON JY: Human cytomegalovirus latency and reactivation - a delicate balance between the virus and its host's immune system. Intervirology (1999) 42(5-6):314–321.
   PubMed Web of Science ®Google Scholar
• HENDRIX MG, SALIMANS MM, VAN BOVEN CP, BRUGGEMAN CA: High prevalence of latently present cytomegalovirus in arterial walls of patients suffering from grade III atherosclerosis. Am. J. Pathol. (1990) 136(1):23–28.
   PubMed Web of Science ®Google Scholar
• MCDONALD K, RECTOR TS, BRAULIN EA, KUBO SH, OLIVARI MT: Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am. J. Cardiol. (1989) 64(5):359–362.
   PubMed Web of Science ®Google Scholar
• ZHOU YF, LEON MB, WACLAWIW MA et al.: Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl. J. Med. (1996) 335(9):624–630.
   PubMed Web of Science ®Google Scholar
• ALBER DG, POWELL KL, VALLANCE P, GOODWIN DA, GRAHAME-CLARKE C: Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Circulation (2000) 102(7):779–785.
   PubMed Web of Science ®Google Scholar
• HSICH E, ZHOU YF, PAIGEN B, JOHNSON TM, BURNETT MS, EPSTEIN SE: Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Atherosclerosis (2001) 156(1):23–28.
   PubMed Web of Science ®Google Scholar
• STREBLOW DN, SODERBERG-NAUCLER C, VIEIRA J et al.: The human cytomegalovirus chemokine receptor U528 mediates vascular smooth muscle cell migration. Cell (1999) 99(5):511–520.
   PubMed Web of Science ®Google Scholar